Skip to main content

Fiscal Wizard · Single-issue tearsheet

WVE / Jun 21, 2026 Run #7319

WVE

Wave Life Sciences Ltd.

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's medicines platform, PRISM combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, a GalNAc-conjugated RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; WVE-007, a GalNAc-conjugated small interfering RNA designed to silence INHBE mRNA targeting obesity; WVE-008, a GalNAc-conjugated RNA editing oligonucleotide for the treatment of liver disease; WVE-N531, an exon splicing oligonucleotide for the treatment of Duchenne muscular dystrophy; and WVE-003, an allele-selective oligonucleotide for the treatment of Huntington's disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd. was founded in 2012 and is based in Singapore.

Composite verdict

F 9.6 / 100
Bearish setup · Trend Following 9 drivers · 3 gates blocking
  • Trendline Break
  • Double 7s
  • Aroon Oscillator
Consider long put target Δ ~0.70 · ~35 DTE Bearish setup, Grade A → ITM put target

Industry rank 442nd of 598 in Biotechnology

rescore-sweep
Technical synthesisRegime: downtrend
Bull 0%Evidence: High · 22 signals100% Bear
Momentum Bearish 7Mean-reversion Neutral 45
  • Late-stage trendTrend signals have been live for 98 bars — past the ~60-bar window; momentum edge decays and can reverse late in a move. (medium confidence)
Where value comes fromMargin of safety -99%

Earnings power doesn't cover the capital structure (high debt) — the EPV decomposition isn't meaningful for this name.

Fundamentals Weak

19.2 / 100

Score-bearing fundamentals shown here exclude gate-only risk checks. · 35 metrics shown.

Strongest
Weakest
Days Sales Outstanding 100
Margin of Safety 0
P/B 75
Free Cash Flow Yield 0
Greenblatt ROC 68
Revenue Growth (YoY) 0

Technicals Bearish

0.1 / 100

Bearish setup leads (Trendline Break, Double 7s, Aroon Oscillator); bulls gated by guards. · 43 signals shown.

Strongest
Weakest
Trendline Break 14
Double 7s 18
Aroon Oscillator 21

Risk Gates

3 blocking 5 caution

3 guards active, 18 signals gated.

Piotroski F-Score Blocking

Bottom-band Piotroski F blocks bullish signals — fundamental-quality risk.

MA Crossover Blocking

Blocks counter-regime signals only when the MA crossover agrees with the long-term regime.

Regime Filter Blocking

Blocks signals that oppose the long-term moving-average regime.

Cash Ratio Caution

Visual cash-cushion flag — does not mute signals.

Breakdown

Look under the hood

Empty pane

Pick a category, above, to crack it open.

Every chip in either subscore card drills into the metrics or signals that fed it — including the formula, the threshold band, and what the current reading means for WVE.